Short answer · Medically reviewed summary · Last updated: 2026-04-07
Sanfilippo Syndrome, or Mucopolysaccharidosis Type III (MPS III), was first described in 1963 by Dr. Sylvester Sanfilippo and his colleagues, who identified it as a unique form of metabolic disorder characterized by severe central nervous system degeneration.
3 people with Sanfilippo Syndrome have shared their first-person experience on this question at DiseaseMaps.
What is the history of Sanfilippo Syndrome?
History of Sanfilippo Syndrome: when and how it was discovered, and the milestones in research since, medically reviewed.
Sanfilippo Syndrome, or Mucopolysaccharidosis Type III (MPS III), was first described in 1963 by Dr. Sylvester Sanfilippo and his colleagues, who identified it as a unique form of metabolic disorder characterized by severe central nervous system degeneration. Since its initial classification, medical understanding has evolved from viewing it as a broad clinical syndrome to identifying four distinct genetic subtypes (A, B, C, and D) caused by specific enzyme deficiencies that prevent the breakdown of heparan sulfate.
How was Sanfilippo Syndrome first identified?
The history of Sanfilippo Syndrome began in 1963 when Dr. Sylvester Sanfilippo published a landmark paper describing eight children who presented with a unique constellation of symptoms, including intellectual disability, behavioral challenges, and mild physical changes. Before this, these children were often grouped under broader categories of "gargoylism" or general mucopolysaccharidoses. By isolating these specific cases, Dr. Sanfilippo and his team provided the foundation for recognizing that Sanfilippo Syndrome was a distinct, genetically driven metabolic condition that primarily affected the brain, rather than just the skeletal system.
How has our understanding of the disease evolved?
In the decades following its discovery, researchers realized that Sanfilippo Syndrome is not one disease but four, each caused by a deficiency in a different enzyme required to break down the sugar chain heparan sulfate. This accumulation of undegraded material in the lysosomes causes the progressive damage seen in the nervous system, skeletal system, and other body systems. Modern genetics has transformed our understanding of Sanfilippo Syndrome, moving from purely clinical observation to molecular diagnosis, allowing families to identify the specific subtype (A, B, C, or D) through precise genetic testing.
What are the major milestones in treatment development?
For many years, the management of Sanfilippo Syndrome was strictly palliative, focusing on symptom management such as managing insomnia and behavioral hyperactivity. However, the last two decades have seen a shift toward disease-modifying research. Notable milestones include:
- Substrate Reduction Therapy: Use of agents like genistein isoflavones and Miglustat to potentially slow the buildup of heparan sulfate.
- Enzyme Replacement Therapy (ERT): Ongoing clinical trials for types A and B that aim to provide the missing enzymes directly to the body.
- Gene Therapy: Recent breakthroughs in gene therapy aim to address the root cause of Sanfilippo Syndrome by introducing functional copies of the affected genes into the patient's cells.
- Autophagy Stimulation: Research into compounds like trehalose, which help cells clear accumulated waste products.
How has the patient advocacy landscape changed?
The evolution of patient advocacy has been instrumental in the progress of Sanfilippo Syndrome research. As families connected globally, groups like the Team Sanfilippo Foundation emerged, driving funding toward high-risk, high-reward studies that traditional pharmaceutical companies might have overlooked. Today, the DiseaseMaps.org community serves as a vital network, with 114 members currently sharing their lived experiences, which helps bridge the gap between clinical data and the daily reality of managing this complex condition.
Next steps
- Consult a metabolic specialist or a geneticist to confirm your specific subtype and discuss current clinical trial eligibility.
- Connect with the community at DiseaseMaps.org to share experiences with others navigating the same journey.
- Reach out to organizations like the National MPS Society or the Team Sanfilippo Foundation for the latest updates on emerging therapies and patient resources.
Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.
References
- NIH Genetic and Rare Diseases Information Center (GARD): Mucopolysaccharidosis type III.
- Orphanet: Mucopolysaccharidosis type III (Sanfilippo syndrome).
- OMIM (Online Mendelian Inheritance in Man): MPS3A, MPS3B, MPS3C, and MPS3D entries.
- National MPS Society: Resources and history of Sanfilippo Syndrome.
In the past, children with Sanfilippo Syndrome were often times misdiagnosed with Hunter or Hurler Syndromes. Today there are still many children misdiagnosed, with Autism added to the list of wrongly identified disorders.
Posted Jan 1, 2018 by Danielle 3160
Posted Feb 25, 2019 by Patty Jesse 3000
Posted Nov 3, 2019 by Anne-marie 2500
